Clinical trials: Neoplasm, Esophageal
Esophageal Cancer
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00109850
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- 132 sites in United States
- Volunteers
- 22 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer, Esophageal Cancer
Perspectives of Receiving Open Versus Minimally Invasive Surgery
This study will examine the perspectives of patients' undergoing surgery for lung or esophageal cancer. It will examine both pre-op and post-op patient perspectives and opinions regarding pain and surgical complications.
- Trial name
- PROMIS (NCT01807390)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Background: It is estimated that in the Netherlands each year approximately 900 patients with gastric cancer or adenocarcinoma of the gastro-oesophageal junction are candidates for chemotherapy.
- Trial name
- B-DOCT (NCT01359397)
- Testing
- Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Recurrence
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor.
- Conditions
- Esophageal Cancer, Recurrence, DNA Methylation
- Trial name
- NCT06476067
- Testing
- Surgery
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Lung Cancer, Small Cell, Pancreatic Cancer
Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Accurate evaluation of activity status is an important part of the assessment of people with cancer. Clinician assessments currently used are valuable but have limitations; in particular, assessment only occurs when the patient…
- Conditions
- Lung Cancer, Small Cell, Pancreatic Cancer, Gastric Cancer, Oesophageal Cancer
- Trial name
- WATTOX (NCT04440800)
- Testing
- Wearable activity tracker - FitBit
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lung Cancer, Esophageal Cancer
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT.
- Conditions
- Lung Cancer, Esophageal Cancer, Thoracic Cancer, Hodgkin Lymphoma
- Trial name
- NCT04072393
- Testing
- Home-based cardiac rehabilitation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Esophageal Squamous Cell Carcinoma
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
Comparison of esophagectomy with Two-field Versus Three-field lymphadenectomy in locally advanced ESCC patients after neoadjuvant therapy
- Trial name
- NCT05420480
- Testing
- Two-Field lymph node dissection, Three-Field lymph node dissection
- Where
- China
- Volunteers
- 323 people
- Sponsor
- Shanghai Zhongshan Hospital
Barrett's Esophagus, Esophageal Adenocarcinoma
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Subjects enrolled in this study will have biopsies obtained and sent to Dr. Fitzgerald's lab for analysis of a validated biomarker panel.
- Conditions
- Barrett's Esophagus, Esophageal Adenocarcinoma, Intestinal Metaplasia, Dysplasia
- Trial name
- NCT02075905
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 111 people
- Sponsor
- University of North Carolina, Chapel Hill
Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus
Single arm phase II PDR001( 300mg, IV) will be treated every 3 weeks
- Trial name
- NCT03785496
- Testing
- PDR001
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Yonsei University
Head Neck Cancer, Oral Cancer
Swallowing Function in Patients With Head and Neck Cancers
Head and neck cancer (HNC) is the sixth most common cancer worldwide, accounting for 2.8% of all malignancies. The presence of tumor itself, as well as the treatment, can result in neuromuscular damage affecting any stage of the…
- Trial name
- NCT05833841
- Testing
- Surface Electromyography and Video fluoroscopy
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Banaras Hindu University
GASTROINTESTINAL NEOPLASMS
Longitudinal Study on the Evolution Trend and Influencing Factors of Postoperative Reflux of Esophageal Cancer Based on PEPTEST Technique
The goal of this observational study intends to explore the evolution trend and related factors of postoperative reflux of esophageal cancer based on PEPTEST detection, in order to identify postoperative reflux The main question…
- Trial name
- NCT06509022
- Testing
- PEPTEST test
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer
- Trial name
- NCT00098527
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
This randomized study examines how well zinc works in improving quality of life in patients with gastrointestinal cancer that cannot be removed by surgery who are receiving chemotherapy.
- Conditions
- Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Unresectable Esophageal Carcinoma, Unresectable Pancreatic Carcinoma
- Trial name
- NCT03819088
- Testing
- Zinc
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Esophageal Neoplasm, Chemoradiation
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
In this phase II study, the investigators aim to evaluated the efficacy and toxicity of definitive concurrent chemoradiotherapy (CCRT) with docetaxel plus cisplatin (DP regimen) versus 5-fluorouracil plus cisplatin (PF regimen)…
- Trial name
- NCT02969473
- Testing
- Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhu Yujia
Barrett's Esophagus
A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy
The primary objective of this study is to determine the percentage segment regression after spray cryotherapy in a dose-escalation study performed in patients with dysplastic Barrett's Esophagus (BE) using trūFreeze™ spray…
- Trial name
- DOSE (NCT01845454)
- Testing
- trūFreeze™ Spray Cryotherapy
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- CSA Medical, Inc.